Who is the CEO of Novartis?

Vasant (Vas) Narasimhan, since 2018, as the AsOf record states with its sources.

Record

Novartis as of November 12, 2025 · AsOf

Viewing the record as of November 12, 2025. Facts, events and changes are as the record holds them for that day. Back to today

organization

Novartis

As of November 12, 2025, Novartis was a Swiss-American multinational pharmaceutical corporation, headquartered in Basel. Its CEO was Vasant (Vas) Narasimhan, since 2018.

CEO: Vasant (Vas) Narasimhan since 2018 sec.gov
Headquarters: Basel sec.gov
Ticker: NVS · NYSE sec.gov

See this record on another date

Compare the record on two dates →

Models, products and related entities are not dated to November 12, 2025, so they are left out here. They are on today’s record.

State as of 2025-11-12

3 assertedThe record stands behind this value for the day asked: two independent sources agree, or a primary source states it (alone, at confidence 0.7 or more). Everything else stays on the record, labelled.More in About → facts

Novartis: state as of 2025-11-12, one row per fact with its value, date, confidence and sources
fact	value	valid fromThe day the value took effect, not the day it was published. A period figure (a year's revenue) is dated at the period's end.More in About →	confidenceHow well the sources support the value, from 0 to 1. A single primary source is asserted from 0.7; nothing below 0.5 is asserted; a dead or disagreeing source lowers it.More in About →	sourcesPrimary: the entity's own filing, feed or site. Secondary: a publisher reporting it. Each claim links every source it has, with the passage that states the value where one was read.More in About →

Latest

0 dated events · full timeline →

No dated events on the record yet.

Releases, deals, appointments and policy changes land here once a checked source dates them.

Every claim on the timeline, including undated ones →

Financials

latest period on record · change vs prior year

Net income

$11.94B

2024-12-31-19.6%

every net income figure →

Operating income

$14.54B

2024-12-31+48.9%

every operating income figure →

Total assets

$102.25B

2024-12-31+2.3%

As reported in the linked filings, which may be restated. Not investment advice.

State changes since 2025-05-16

0 changes

No changes since 2025-05-16.

Widen the window with the since date, or compare two dates with the diff.

The full timeline →

About this record

Identifiers9 keys · schema.org snippet

AsOf ID: ent_novartis
Wikidata: Q507154
X: Novartis
SEC CIK: 0001114448
fiscal year end: 12-31
SIC industry: Pharmaceutical Preparations (2834)
incorporated in: V8
ticker: NVS
website: www.novartis.com

Cite this record in schema.org

"sameAs": ["https://www.wikidata.org/wiki/Q507154", "https://asof.is/record/novartis"],
"identifier": { "@type": "PropertyValue", "propertyID": "asof", "value": "ent_novartis" }

Paste into the entity's JSON-LD. Why and how.

Sources on this entity5 sites · 66 citations

sec.govprimary · 59

62 claims on record, 19 currently valid, 43 superseded. Last change 2024-12-31.

Country	Switzerland undatednovartis.com+2: 3 sources for country, claim clm_583E79DC8FFB	undated	0.80	novartis.com+2: 3 sources for country, claim clm_583E79DC8FFB
Shares outstanding	1.98B shares 2024-12-31sec.gov: 1 source for shares outstanding, claim clm_5B7C7456996A	2024-12-31	0.95	sec.gov: 1 source for shares outstanding, claim clm_5B7C7456996A
Total equity	$44.13B 2024-12-31sec.gov: 1 source for total equity, claim clm_DD45194F44A3	2024-12-31	0.95	sec.gov: 1 source for total equity, claim clm_DD45194F44A3